Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909014 | 1.00 | TNKS2 (0.40) | TNKS2PARP2TOP2ASMN1; SMN2TSHR | |
| SCHEMBL30146470 | 0.79 | MAPT (0.38) | MAPT | |
| SCHEMBL30013514 | 0.77 | KDM4E (0.35) | HSD17B10LMNAMAOAKDM4EMAPT | |
| SCHEMBL30961068 | 0.77 | KMO (0.36) | KDM4EMAPT | |
| SCHEMBL30578403 | 0.75 | TSHR (0.39) | TNKS2PARP2TOP2ASMN1; SMN2TSHR | |
| SCHEMBL1598267 | 0.73 | SMN1; SMN2 (0.50) | TNKS2PARP2TOP2ASMN1; SMN2TSHR | |
| SCHEMBL30013801 | 0.73 | SMN1; SMN2 (0.50) | TNKS2PARP2TOP2ASMN1; SMN2TSHR | |
| SCHEMBL5909487 | 0.72 | BACE1 (0.40) | HSD17B10HPGDKDM4EMAPT | |
| SCHEMBL31605956 | 0.72 | BACE1 (0.40) | HSD17B10HPGDKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL11775175 | 0.72 | SMN1; SMN2 (0.49) | TNKS2PARP2TOP2ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4002755-A | Triazoloquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-01-11 | — | — | US | claimed |
| US-10702518-B2 | TAF1 inhibitors for the therapy of cancer | CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH (AT) | 2020-07-07 | — | — | US | disclosed |
| US-20190117641-A1 | TAF1 INHIBITORS FOR THE THERAPY OF CANCER | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2019-04-25 | — | — | US | disclosed |
| WO-2016001452-A1 | COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED | Universität Zürich (CH) | 2016-01-07 | — | — | WO | disclosed |
| US-5998423-A | IN SKIN OR HAIR; ADMINISTERING ADENOSINE RECEPTOR ANTAGONIST | THERASYS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-4002755-A | Triazoloquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117641-A1 | TAF1 INHIBITORS FOR THE THERAPY OF CANCER | TAF1, TAF1L, TAF5 | TNKS2 520/4885PARP2 504/4885TOP2A 345/4885 |
| US-10702518-B2 | TAF1 inhibitors for the therapy of cancer | TAF1, TAF1L, TAF5 | TNKS2 520/4885PARP2 504/4885TOP2A 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.